Cutaneous T-Cell Lymphoma (CTCL) Completed Phase 2 Trials for Tislelizumab (DB14922)

Also known as: Cutaneous T Cell Lymphoma (CTCL) / Cutaneous T Cell Lymphomas (CTCL) / Cutaneous T-Cell Lymphoma / Cutaneous T Cell Lymphoma / Cutaneous T-Cell Lymphomas / CTCL / Primary cutaneous T-cell lymphoma (morphologic abnormality) / Cutaneous T-cell lymphoma (morphologic abnormality) / Primary cutaneous T-cell lymphoma (disorder) / Lymphoma, T-Cell, Cutaneous

IndicationStatusPhase
DBCOND0071861 (Cutaneous T-Cell Lymphoma (CTCL))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03493451Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell NeoplasmsTreatment